New legislation on medical devices
The new European legislation on medical devices was to have come into force on 26 May 2020. This legislation is laid down in the so-called ‘Medical Device Regulation’ (MDR), which was agreed by th ...
Recent articles
No melatonin for primary sleep disorders
Even though it has been known for years that melatonin has limited efficacy for the treatment of primary sleep disorders, this agent is still frequently used for this purpose. Recent randomised st ...
Lymphoma due to breast implants?
Breast Implant Associated – Anaplastic Large Cell Lymphoma (BIA-ALCL) is currently the only complication of breast implants for which a causal relationship is likely. The risk of BIA-ALCL is about ...
Negative influence of drugs on COVID-19
The new coronavirus (SARS-CoV-2) is raising many questions among care providers, including questions about the use of drugs that could have a negative influence on the course of the COVID-19 dise ...
Menopausal hormone therapy and breast cancer
Research findings published in 2019 lend support to the view that the risk of hormone therapy for menopausal symptoms in women might be underestimated. There has been ongoing debate for years abou ...
Genotyping prior to clopidogrel treatment?
Clopidogrel, which is used as a platelet aggregation inhibitor for the prophylaxis of atherothrombotic complications, is enzymatically activated by the enzyme CYP2C19. Patients whose genetic predi ...
Drug interactions with CYP enzymes
Cytochrome P450 enzymes (CYP enzymes) are involved in the metabolism of many drugs. Since the activity of CYP enzymes can be inhibited or stimulated by other drugs, a large variety of interactions ...
Level of evidence: randomised or observational studies?
Randomised controlled trials (RCT’s) are regarded as the gold standard in medical research to prove whether presumed effects of medicinal or other treatments are of a causal nature. There may howe ...
